Antiphospholipid syndrome and Idiopathic retroperitoneal fibrosis

Summary:

Idiopathic retroperitoneal fibrosis is reported only by a few people with Antiphospholipid syndrome.

The study analyzes which people have Idiopathic retroperitoneal fibrosis with Antiphospholipid syndrome. It is created by eHealthMe based on 1 person who has Idiopathic retroperitoneal fibrosis and Antiphospholipid syndrome from the Food and Drug Administration (FDA), and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Feb, 07, 2023

1 person who has Antiphospholipid Syndrome and Idiopathic Retroperitoneal Fibrosis is studied.


What is Antiphospholipid syndrome?

Antiphospholipid syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss) is found to be associated with 657 drugs and 361 conditions by eHealthMe.

What is Idiopathic retroperitoneal fibrosis?

Idiopathic retroperitoneal fibrosis (disorder that blocks the tubes (ureters) that carry urine) is found to be associated with 509 drugs and 368 conditions by eHealthMe.

Number of Idiopathic retroperitoneal fibrosis in Antiphospholipid syndrome reports submitted per year:

Would you have Idiopathic retroperitoneal fibrosis when you have Antiphospholipid syndrome?

Gender of people who have Antiphospholipid Syndrome and experienced Idiopathic Retroperitoneal Fibrosis *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Antiphospholipid Syndrome and experienced Idiopathic Retroperitoneal Fibrosis *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 100 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common co-existing conditions for these people *:

  1. Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 100.00%
  2. Osteoporosis (bones weak and more likely to break): 1 person, 100.00%
  3. Neuralgia (pain in one or more nerves): 1 person, 100.00%
  4. Lupus Nephritis (a chronic inflammatory autoimmune disorder that may affect kidney tissue): 1 person, 100.00%
  5. Kidney Infection (Pyelonephritis): 1 person, 100.00%
  6. Insomnia (sleeplessness): 1 person, 100.00%
  7. High Blood Pressure: 1 person, 100.00%
  8. Haematoma (collection of blood outside the blood vessels): 1 person, 100.00%
  9. Gastric Ulcer (stomach ulcer): 1 person, 100.00%

Common drugs taken by these people *:

  1. Prograf: 1 person, 100.00%
  2. Medrol: 1 person, 100.00%
  3. Lyrica: 1 person, 100.00%
  4. Evista: 1 person, 100.00%
  5. Ciclosporin: 1 person, 100.00%
  6. Blopress: 1 person, 100.00%

Common symptoms for these people *:

  1. Myopathy (a muscular disease in which the muscle fibres do not function): 1 person, 100.00%
  2. Blood Beta-D-Glucan Increased: 1 person, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Idiopathic retroperitoneal fibrosis?

Check whether Idiopathic retroperitoneal fibrosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Treatments, associated drugs and conditions:

COVID vaccines that are related to Idiopathic retroperitoneal fibrosis:

All the drugs that are associated with Idiopathic retroperitoneal fibrosis:

All the conditions that are associated with Idiopathic retroperitoneal fibrosis:

How the study uses the data?

The study is based on Idiopathic retroperitoneal fibrosis and Antiphospholipid syndrome, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: